Expert Consensus on the Treatment of Antiangiogenic Agents for Radiation Brain Necrosis.
10.3779/j.issn.1009-3419.2022.101.18
- Author:
Yi CHEN
1
;
Xin WANG
2
;
Bing SUN
3
;
Maobin MENG
4
;
Enmin WANG
2
;
Zhiyong YUAN
4
;
Hongqing ZHUANG
1
Author Information
1. Department of Radiation Oncology, Peking University Third Hospital, Beijing 100191, China.
2. Department of Radiation Oncology, Fudan University Huashan Hospital, Shanghai 200000, China.
3. Department of Radiation Oncology, The Fifth Medical Center of PLA General Hospital, Beijing 100000, China.
4. Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300000, China.
- Collective Name:Society of Radiation Oncology, Chinese Medical Education Association
- Publication Type:Journal Article
- Keywords:
Antiangiogenic drugs;
Bevacizumab;
Expert consensus;
Radioactive brain necrosis
- MeSH:
Angiogenesis Inhibitors/pharmacology*;
Bevacizumab/therapeutic use*;
Brain/metabolism*;
Consensus;
Humans;
Lung Neoplasms/drug therapy*;
Necrosis/etiology*;
Radiation Injuries/etiology*;
Vascular Endothelial Growth Factor A/metabolism*
- From:
Chinese Journal of Lung Cancer
2022;25(5):291-294
- CountryChina
- Language:Chinese
-
Abstract:
Vascular damage is followed by vascular endothelial growth factor (VEGF) expression at high levels, which is an important mechanism for cerebral radiation necrosis (CRN) development. Antiangiogenic agents (Bevacizumab) alleviates brain edema symptoms caused by CRN through inhibiting VEGF and acting on vascular tissue around the brain necrosis area. Many studies have confirmed that Bevacizumab effectively relieves symptoms caused by brain necrosis, improves patients' performance status and brain necrosis imaging. Considering that the efficacy of antiangiogenic therapy is mainly related to the duration of drug action, low-dose antiangiogenic agents can achieve favorable efficacy. Prevention is the best treatment. The occurrence of CRN is associated with tumor-related factors and treatment-related factors. By controlling these factors, CRN can be effectively prevented.
.
